Skip to main content
Erschienen in: International Journal of Clinical Oncology 2/2020

04.10.2019 | Original Article

Clinicopathologic characteristics of malignant non-hematopoietic tumors first presented as an axillary mass with emphasis on occult breast carcinoma

verfasst von: Thaer Khoury, Ana Lucia Ruano Mendez, Xuan Peng, Li Yan, Emilian Racila

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Non-hematopoietic malignancies first presented as an axillary mass constitute a unique clinical presentation. We investigated the incidence of various types of malignancies and aimed to define clinicopathologic variables that may assist in the diagnosis, with focus on occult breast carcinoma (OBC).

Design

We reviewed the pathology reports of cases with non-hematopoietic malignancies of the axillary region in our institution between 2000 and 2016. We included patients who presented first with axillary mass and with the absence of a known primary. We recorded patients’ age and gender, tumor characteristics including size, histologic type, number of positive lymph nodes, and the clinical management. Then we focused on BC which were divided into OBC or primary BC (PBC).

Results

There were 100 cases that met our criteria (28 melanoma, 7 sarcoma and 65 carcinoma). For carcinoma cases, there were 42 BC (19 OBC, 17 PBC, and 6 possible OBC), 17 non-BC, and 6 carcinoma of unknown primary (CUP). Tumors found incidentally were more likely to be of breast primary (p = 0.01). Larger tumor size (in mm) favored melanoma or sarcoma over BC, non-BC carcinoma or CUP with median and range 61 (15, 180), 60 (23, 80), 30 (15, 75), 31 (17, 90), 26 (20, 55), respectively (p < 0.001). There were no differences in the histopathologic findings or clinical presentation.

Conclusions

More than half of the patients with axillary malignancy have a tumor of non-breast origin. Therefore, clinical and pathologic studies are warranted to identify the primary site.
Literatur
1.
Zurück zum Zitat Gupta A, Metcalf C, Taylor D (2017) Review of axillary lesions, emphasising some distinctive imaging and pathology findings. J Med Imaging Radiat Oncol 61(5):571–581CrossRef Gupta A, Metcalf C, Taylor D (2017) Review of axillary lesions, emphasising some distinctive imaging and pathology findings. J Med Imaging Radiat Oncol 61(5):571–581CrossRef
2.
Zurück zum Zitat Walsh R, Kornguth PJ, Soo MS et al (1997) Axillary lymph nodes: mammographic, pathologic, and clinical correlation. AJR Am J Roentgenol 168(1):33–38CrossRef Walsh R, Kornguth PJ, Soo MS et al (1997) Axillary lymph nodes: mammographic, pathologic, and clinical correlation. AJR Am J Roentgenol 168(1):33–38CrossRef
3.
Zurück zum Zitat Muttarak M, Chaiwun B, Peh WC (2004) Role of mammography in diagnosis of axillary abnormalities in women with normal breast examination. Australas Radiol 48(3):306–310CrossRef Muttarak M, Chaiwun B, Peh WC (2004) Role of mammography in diagnosis of axillary abnormalities in women with normal breast examination. Australas Radiol 48(3):306–310CrossRef
4.
Zurück zum Zitat Kirova AFAYM. Occult primary cancer with axillary metastases. In: Harris JR, Morrow M, Osborne CK, editor. Diseases of the breast, 5th edn. Philadelphia: Wolters Kluwer Health; 2014. p. 864–9. Kirova AFAYM. Occult primary cancer with axillary metastases. In: Harris JR, Morrow M, Osborne CK, editor. Diseases of the breast, 5th edn. Philadelphia: Wolters Kluwer Health; 2014. p. 864–9.
5.
Zurück zum Zitat Kamposioras K, Pentheroudakis G, Pectasides D et al (2011) Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 78(2):112–126CrossRef Kamposioras K, Pentheroudakis G, Pectasides D et al (2011) Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 78(2):112–126CrossRef
6.
Zurück zum Zitat Chan JK, Suster S, Wenig BM et al (1997) Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol 21(2):226–234CrossRef Chan JK, Suster S, Wenig BM et al (1997) Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol 21(2):226–234CrossRef
7.
Zurück zum Zitat Kandalaft PL, Gown AM (2016) Practical applications in immunohistochemistry: carcinomas of unknown primary site. Arch Pathol Lab Med 140(6):508–523CrossRef Kandalaft PL, Gown AM (2016) Practical applications in immunohistochemistry: carcinomas of unknown primary site. Arch Pathol Lab Med 140(6):508–523CrossRef
8.
Zurück zum Zitat Compton LA, Murphy GF, Lian CG (2015) Diagnostic immunohistochemistry in cutaneous neoplasia: an update. Dermatopathology (Basel, Switzerland) 2(1):15–42 Compton LA, Murphy GF, Lian CG (2015) Diagnostic immunohistochemistry in cutaneous neoplasia: an update. Dermatopathology (Basel, Switzerland) 2(1):15–42
9.
Zurück zum Zitat Miettinen M (1991) Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am J Pathol 138(2):505–513PubMedPubMedCentral Miettinen M (1991) Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am J Pathol 138(2):505–513PubMedPubMedCentral
10.
Zurück zum Zitat Reis-Filho JS, Gobbi H, Sneige N. Metaplastic carcinoma. In: Lakhani SR, Schnitt SJ, Tan PH, van de Vijver MJ, editor. WHO classification of tumours of the breast, 4th edn. Lyon: International agency for research (IARC); 2001. p. 48–52. Reis-Filho JS, Gobbi H, Sneige N. Metaplastic carcinoma. In: Lakhani SR, Schnitt SJ, Tan PH, van de Vijver MJ, editor. WHO classification of tumours of the breast, 4th edn. Lyon: International agency for research (IARC); 2001. p. 48–52.
11.
Zurück zum Zitat Varadhachary GR, Raber MN (2014) Cancer of unknown primary site. N Engl J Med 371(8):757–765CrossRef Varadhachary GR, Raber MN (2014) Cancer of unknown primary site. N Engl J Med 371(8):757–765CrossRef
12.
Zurück zum Zitat Ross JS, Wang K, Gay L et al (2015) Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 1(1):40–49CrossRef Ross JS, Wang K, Gay L et al (2015) Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 1(1):40–49CrossRef
13.
Zurück zum Zitat Moran S, Martinez-Cardus A, Sayols S et al (2016) Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol 17(10):1386–1395CrossRef Moran S, Martinez-Cardus A, Sayols S et al (2016) Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol 17(10):1386–1395CrossRef
14.
Zurück zum Zitat Shatzel J, Blum A, Khoury T et al (2013) Gynecomastia-like hyperplasia of axillary ectopic breast tissue in a young female. Case Rep Pathol 2013:634248PubMedPubMedCentral Shatzel J, Blum A, Khoury T et al (2013) Gynecomastia-like hyperplasia of axillary ectopic breast tissue in a young female. Case Rep Pathol 2013:634248PubMedPubMedCentral
15.
Zurück zum Zitat de Bresser J, de Vos B, van der Ent F et al (2010) Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 36(2):114–119 de Bresser J, de Vos B, van der Ent F et al (2010) Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 36(2):114–119
16.
Zurück zum Zitat Montagna E, Bagnardi V, Rotmensz N et al (2011) Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 129(3):867–875CrossRef Montagna E, Bagnardi V, Rotmensz N et al (2011) Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 129(3):867–875CrossRef
17.
Zurück zum Zitat Wang X, Zhao Y, Cao X (2010) Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast J 16(1):32–37CrossRef Wang X, Zhao Y, Cao X (2010) Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast J 16(1):32–37CrossRef
18.
Zurück zum Zitat Barton SR, Smith IE, Kirby AM et al (2011) The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer 47(14):2099–2106CrossRef Barton SR, Smith IE, Kirby AM et al (2011) The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer 47(14):2099–2106CrossRef
Metadaten
Titel
Clinicopathologic characteristics of malignant non-hematopoietic tumors first presented as an axillary mass with emphasis on occult breast carcinoma
verfasst von
Thaer Khoury
Ana Lucia Ruano Mendez
Xuan Peng
Li Yan
Emilian Racila
Publikationsdatum
04.10.2019
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 2/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01555-2

Weitere Artikel der Ausgabe 2/2020

International Journal of Clinical Oncology 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.